FENNEC (NASDAQ: FENC) director receives fully vested options for 20,000 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
FENNEC PHARMACEUTICALS INC. director Marco Maria Brughera received a grant of stock options as part of his compensation. On June 10, 2026, he was awarded a non-qualified option to purchase 20,000 common shares at an exercise price of $8.70 per share, fully vested on the grant date. Following this grant, his reported option holdings increased to 235,545 derivative securities, indicating this is a routine equity incentive award rather than an open-market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Brughera Marco Maria
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 20,000 | $8.70 | $174K |
Holdings After Transaction:
Stock Option — 235,545 shares (Direct, null)
Footnotes (1)
- On June 10, 2026, Marco Brughera was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. The option is 100% vested on date of grant.
Key Figures
Option grant size: 20,000 shares
Exercise price: $8.70 per share
Post-grant derivative holdings: 235,545 options
+2 more
5 metrics
Option grant size
20,000 shares
Non-qualified stock option granted June 10, 2026
Exercise price
$8.70 per share
Strike price for 20,000-share option grant
Post-grant derivative holdings
235,545 options
Total derivative securities following the transaction
Grant date
June 10, 2026
Date option was granted and fully vested
Option expiration
June 10, 2036
Expiration date of the granted stock option
Key Terms
non-qualified stock option, Equity Incentive Plan, fully vested, exercise price, +1 more
5 terms
non-qualified stock option financial
"Marco Brughera was granted a non-qualified stock option to purchase 20,000 shares"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Equity Incentive Plan financial
"pursuant to the issuer's Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
fully vested financial
"The option is 100% vested on date of grant"
exercise price financial
"to purchase 20,000 shares ... at an exercise price of $8.70"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
derivative securities financial
"total_shares_following_transaction 235545.0000 derivative securities"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
What did FENNEC PHARMACEUTICALS INC. (FENC) director Marco Brughera report on this Form 4?
Marco Brughera reported receiving a grant of stock options to buy 20,000 FENNEC PHARMACEUTICALS common shares. The options were awarded on June 10, 2026 at an exercise price of $8.70 per share and are part of his equity-based compensation under the company’s incentive plan.
Is the June 10, 2026 FENC Form 4 for an insider stock purchase or a compensation grant?
The Form 4 reflects a compensation-related grant, not an open-market stock purchase. Brughera received a non-qualified stock option to purchase 20,000 common shares at $8.70 per share, fully vested on the grant date, under FENNEC PHARMACEUTICALS’ Equity Incentive Plan.
What are the key terms of Marco Brughera’s new FENC stock options?
The grant covers 20,000 common shares at an exercise price of $8.70 per share. It is a non-qualified stock option, fully vested on June 10, 2026, and is exercisable until its stated expiration date of June 10, 2036, according to the filing footnotes.
How many FENNEC PHARMACEUTICALS derivative securities does Marco Brughera hold after this grant?
After the June 10, 2026 grant, Brughera is reported to hold 235,545 derivative securities in the form of stock options. This total includes the newly granted 20,000-share option and provides context for the scale of this single compensation award in his overall option position.
When do Marco Brughera’s newly granted FENC stock options vest and expire?
The options are 100% vested on the June 10, 2026 grant date, meaning they are immediately exercisable. According to the filing, these non-qualified stock options carry an expiration date of June 10, 2036, giving a 10-year window during which they can be exercised.